Clinical companies

Syncona’s clinical companies have screened and enrolled the first patient into a clinical trial and are scaling towards late-stage development.

Syncona’s clinical portfolio comprises companies with the potential to treat patients across a range of conditions including: non-small cell lung cancer, melanoma, adrenomyeloneuropathy, Gaucher disease and liver transplantation using a variety of modalities, including cell therapy, gene therapy and biologics.

Key facts

Unless stated all financials at 30 September 2023.


Value of clinical portfolio


Number of clinical trials


Portfolio company Board seats

Our clinical stage portfolio companies

The clinical stage portfolio pipeline